showed that an early increase in circulating CX3CR1+ CD8+ T cells following anti‐PD‐1 therapy correlates with better treatment response and survival in NSCLC.[131] Likewise, Kamphorst et al. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.